share_log

Needham Maintains Buy on Esperion Therapeutics, Lowers Price Target to $10

Needham Maintains Buy on Esperion Therapeutics, Lowers Price Target to $10

Needham 維持對Esperion Therapeutics的買入,將目標價下調至10
Benzinga ·  2023/05/09 12:27

Needham analyst Serge Belanger maintains Esperion Therapeutics (NASDAQ:ESPR) with a Buy and lowers the price target from $12 to $10.

Needham分析師塞爾吉·貝蘭格維持Esperion Therapeutics(納斯達克股票代碼:ESPR)的買入,並將目標股價從12美元下調至10美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論